RxDoctor Payments Data

Ashraf Hanna, MD

Family Medicine · Fort Wayne, INNPI 1720153919

Payments from drug & device makers

$12,213in general payments, 2019–2025

Across 513 payments — averaging $23.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$2K
  • Johnson & Johnson$1K
  • AstraZeneca$826
  • Novo Nordisk$752
  • Amgen$669
  • plus $5K from 31 others

What the payments were for

  • Food & beverage$12,207100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,213 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$68,867
Medicare patients
366
Services billed
4,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide33$68,858
JardianceEmpagliflozin43$56,194
MounjaroTirzepatide36$46,110
OzempicSemaglutide21$36,717
EliquisApixaban24$27,570
FarxigaDapagliflozin Propanediol26$23,730
LinzessLinaclotide17$14,957
XareltoRivaroxaban16$13,881
Potassium Chloride20$10,305
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,129
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$6,574
Insulin Lispro Kwikpen U-100Insulin Lispro14$3,104
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$2,568
Atorvastatin Calcium271$2,276
Aripiprazole16$2,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,683$114,96769 claims
Boehringer IngelheimJardiance$283$56,19443 claims
Novo NordiskOzempic$752$36,71721 claims
PfizerEliquis$62$27,57024 claims
AstraZenecaFarxiga$826$23,73026 claims
AbbVieLinzess, Synthroid$1,798$15,85337 claims
Johnson & JohnsonXarelto$1,049$13,88116 claims
GSKTrelegy Ellipta$651$8,12913 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$26$1,033158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →